Design Therapeutics' GeneTAC platform is revolutionizing genetic disease treatment with small molecules and promising results ...

The recent volatility in our stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy, but I want to reassure our investors that there have ...

SOUTH SAN FRANCISCO, Calif. - Quince Therapeutics, Inc. (NASDAQ: QNCX), a biotech firm focusing on rare diseases with a current market capitalization of $67.76 million, has received a Notice of ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Chief Scientific Officer Yoshitsugu Shitaka, Ph.D., won’t be so lucky. Astellas intends to create the new role of chief ...

Alongside public hearings on Bill 83 to promote the practice of medicine within the public health and social services network, which begin tomorrow, the Point St. Charles Community Clinic and its ...

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going to take a look at where Biogen Inc.

The Schmitt family is grateful for the resources through A-T Children’s Project, as well as the love and care at St. Jude’s, ...

Sep. 5, 2024 — A study investigated the origin of ataxia in the brain of patients ... 2024 — Researchers have designed, in mice, an approach to minimizing the damage from a spinal cord injury ...

Adult-onset genetic and metabolic diseases often present with clinical signs of spinal cord involvement, such as spasticity, weakness, sensory ataxia, impairment of vibration ... In a schematic ...